The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 18, 2023

Filed:

Jan. 10, 2018
Applicant:

Eth Zurich, Zurich, CH;

Inventors:

Joshua Abd Alla, Zurich, CH;

Stefan Wolf, Zurich, CH;

Ursula Quitterer, Zurich, CH;

Assignee:

ETH ZURICH, Zurich, CH;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4025 (2006.01); A61K 31/416 (2006.01); A61K 31/4184 (2006.01); A61K 31/506 (2006.01); A61K 31/541 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4025 (2013.01); A61K 31/416 (2013.01); A61K 31/4184 (2013.01); A61K 31/506 (2013.01); A61K 31/541 (2013.01);
Abstract

The present invention is directed to cell-protective, in particular, cardio- and renal-protective organic compounds, preferably to organic compounds that inhibit substrate phosphorylation by the G-protein-coupled receptor kinase 2 (GRK2, ADRBK1). Preferably, the organic compounds inhibit the GRK2-mediated phosphorylation of serine/arginine-rich splicing factor 1 (SRSF1, ASF-1, SF2) and/or phosducin for treating hypertension, heart diseases, heart dysfunction or failure and heart disease-associated pathologies, e.g. cardiomyocyte necrosis, ischemic cardiac disease and/or ischemic heart damage or ageing. Furthermore, the present invention is directed to a method for the identification of inhibitors of the (GRK2)-mediated phosphorylation of (SRSF1) and/or phosducin.


Find Patent Forward Citations

Loading…